Table 2

Clinical characteristics of AML patients

The cohort was divided into thirds based on rank-order analysis of XIAP protein levels. As discussed in the text, the top two-thirds were collapsed into one group.

All patientsaXIAP LowXIAP HighPa (%)
n c 782652
Male:Female44:3412:1432:200.20
Age (median)5249540.10
Cytogenetics
Favorable120309
Intermediate3515200.27
Unfavorable360828
Antecedent hematological disorder >2 months (%)1812210.29
Zubrod performance status 3 or 4 (%)1200170.02
Complete remission (%)6873650.42
Relapse (%)5542650.17
Alive (%)2942230.004
Median survival (wk)67133520.05
Median remission duration (wk)5787530.13
  • a Patients with blasts >15%.

  • a Compares lower third with top two-thirds.

  • c Number of patients.